Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gust H Bardy

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|January 22, 2005
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failureGust H Bardy, Kerry L Lee, Daniel B Mark, et al.
The New England Journal of Medicine|September 5, 2008
Prognostic importance of defibrillator shocks in patients with heart failureJeanne E Poole, George W Johnson, Anne S Hellkamp, et al.
Journal of the American College of Cardiology|August 9, 2008
No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)Joseph A Blatt, Jeanne E Poole, George W Johnson, et al.
International Journal of Cardiology|January 29, 2014
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?Sana M Al-Khatib, Joo Y Han, Rex Edwards, et al.
Circulation. Cardiovascular Quality and Outcomes|February 12, 2015
Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trialsPaul L Hess, Sana M Al-Khatib, Joo Y Han, et al.
Journal of Cardiovascular Electrophysiology|July 27, 2017
Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT IIEmily P Zeitler, Sana M Al-Khatib, Daniel J Friedman, et al.
JACC. Heart Failure|October 13, 2014
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trialsBenjamin A Steinberg, Sana M Al-Khatib, Rex Edwards, et al.
Circulation|November 18, 2009
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trialDouglas L Packer, Jordan M Prutkin, Anne S Hellkamp, et al.
American Heart Journal|September 11, 2017
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trialsDaniel J Friedman, Sana M Al-Khatib, Emily P Zeitler, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 13, 2014
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trialsPatrick H Pun, Sana M Al-Khatib, Joo Yoon Han, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|January 22, 2005
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failureGust H Bardy, Kerry L Lee, Daniel B Mark, et al.
The New England Journal of Medicine|September 5, 2008
Prognostic importance of defibrillator shocks in patients with heart failureJeanne E Poole, George W Johnson, Anne S Hellkamp, et al.
Journal of the American College of Cardiology|August 9, 2008
No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)Joseph A Blatt, Jeanne E Poole, George W Johnson, et al.
International Journal of Cardiology|January 29, 2014
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?Sana M Al-Khatib, Joo Y Han, Rex Edwards, et al.
Circulation. Cardiovascular Quality and Outcomes|February 12, 2015
Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trialsPaul L Hess, Sana M Al-Khatib, Joo Y Han, et al.
Journal of Cardiovascular Electrophysiology|July 27, 2017
Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT IIEmily P Zeitler, Sana M Al-Khatib, Daniel J Friedman, et al.
JACC. Heart Failure|October 13, 2014
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trialsBenjamin A Steinberg, Sana M Al-Khatib, Rex Edwards, et al.
Circulation|November 18, 2009
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trialDouglas L Packer, Jordan M Prutkin, Anne S Hellkamp, et al.
American Heart Journal|September 11, 2017
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trialsDaniel J Friedman, Sana M Al-Khatib, Emily P Zeitler, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 13, 2014
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trialsPatrick H Pun, Sana M Al-Khatib, Joo Yoon Han, et al.
Pageof 7